In the Zone: ocular cell and gene therapies – why the eye?

The last 10–15 years have seen an increased interest in cell and gene therapies (CGTs). CGTs refer to a group of drug products or therapeutics in which the active pharmaceutical agent is either a gene or cell. Ocular therapies have become a particularly exciting area of focus for CGT research. With several properties that make it an inherently attractive area of research focus for CGTs, such as being immune-privileged, the eye provides a unique opportunity for new and experimental therapies, including CGTs.

INFOGRAPHIC

Ocular cell and gene therapies: why the eye? – This infographic covers key considerations when conducting ocular CGT studies. These considerations include common platforms for CGT bioanalytics, efficacy studies and safety–toxicity studies to conduct, as well as how to generate and provide preclinical information required for investigational new drug applications to enter clinical trials.

WEBINAR

Ophthalmic modalities to evaluate the safety and efficacy of cell and gene therapy products – In this webinar, we highlight current tools and methods available to evaluate the safety and efficacy of ocular CGT products. Learn about in vivo models utilized in preclinical ophthalmology research, selection criteria for animal modles in ocular CGT research and strategies for sophisticated drug-delivery in target ocular compartments.

[Video edit by Lauryn Cushnie]

In association with: